Therapeutic Advances in Hematology

Aims & Scope

Therapeutic Advances in Hematology delivers the highest quality peer-reviewed open access original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of blood disorders.

The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in hematology and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area.

The editors welcome original research articles across all areas of hematology.

The journal publishes original research articles and review articles primarily.

Original research manuscripts may include laboratory, animal or human/clinical studies - all phases.

Letters to the Editor and Case Reports will also be considered.

Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews.

Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed.

The appropriate EQUATOR Network reporting guidelines should be followed (e.g.

CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses).

The journal endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment.

However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable.

Metrics & Ranking

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Directory of Open Access Journals (DOAJ)
• Web of Science
• Embase

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

Policy Links

This section provides access to essential policy documents, guidelines, and resources related to the journal’s publication and submission processes.

• Aims scope
• Homepage
• Oa statement
• Author instructions
• License terms
• Review url
• Board url
• Plagiarism url
• Preservation url
• Apc url

Plagiarism Policy

This journal follows a plagiarism policy. All submitted manuscripts are screened using reliable plagiarism detection software to ensure originality and academic integrity. Authors are responsible for proper citation and acknowledgment of all sources, and any form of plagiarism, including self-plagiarism, will not be tolerated.

For more details, please refer to our official: Plagiarism Policy.

APC Details

The journal’s Article Processing Charge (APC) policies support open access publishing in Medicine, ensuring accessibility and quality in research dissemination.

This journal requires an Article Processing Charge (APC) to support open access publishing, covering peer review, editing, and distribution. The current APC is 2,500,000.00 IRR. Learn more.

Explore journals without APCs for alternative publishing options.

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Myeloid sarcoma: current approach and therapeutic options

  Citation: 189

  Authors: Batia, Maya

• CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products

  Citation: 182

  Authors: Julio C., Christina, Mohamed A.

• Factor VIII inhibitors in hemophilia A: rationale and latest evidence

  Citation: 178

  Authors: Char, Guy

• Treatment and management of graft-<i>versus</i>-host disease: improving response and survival

  Citation: 161

  Authors: Catherine, Jane F., Jiří

• The rise, fall and subsequent triumph of thalidomide: lessons learned in drug development

  Citation: 152

  Authors: Waqas, Lisa M., Hillard M.

• The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond

  Citation: 142

  Authors: Seth A., Mark J., Amir T.

• Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence

  Citation: 140

  Authors: Aristeidis, Valentina, Anastasios

• Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia

  Citation: 106

  Authors: Nicholas J., Hagop, Farhad, Naval

• Management of imatinib-resistant patients with chronic myeloid leukemia

  Citation: 105

  Authors: Pavan Kumar, Hagop, Jorge, A. Megan, Elias

• New and emerging therapies for acute and chronic graft <i>versus</i> host disease

  Citation: 104

  Authors: LaQuisa, Amin, Partow, Rohtesh, Katayoun, Elizabeth